RAGE and its ligands in bone metabolism

Frontiers in Bioscience - Scholar

Volumn 3 S, Issue 2, 2011, Pages 768-776

  Zhou, Zheng ^a   Xiong, Wen Cheng ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

AGE; Bone; HMGB1; Osteoblast; Osteoclasts; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CALGRANULIN; CALVASCULIN; COLONY STIMULATING FACTOR 1; HIGH MOBILITY GROUP B1 PROTEIN; LIGAND; MEMBRANE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN S 100; MITOGEN ACTIVATED PROTEIN KINASE; RAGE PROTEIN, HUMAN; TUMOR ANTIGEN;

ALZHEIMER DISEASE; ARTICLE; BONE CELL; BONE DISEASE; BONE FRAGILITY; BONE LESION; BONE MASS; BONE MATRIX; BONE METABOLISM; BONE MINERALIZATION; BONE REMODELING; CALLUS; CARTILAGE CELL; CELL MATURATION; CHONDROSARCOMA; CHRONIC INFLAMMATION; DIABETES MELLITUS; ENCHONDRAL OSSIFICATION; HUMAN; INNATE IMMUNITY; MACROPHAGE; MESENCHYMAL STEM CELL; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOCYTE; OSTEOID OSTEOMA; OSTEOLYSIS; OSTEOSARCOMA; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; STEM CELL MOBILIZATION; TERATOMA; ANIMAL; METABOLISM; MOUSE; PHYSIOLOGY; REVIEW;

ANIMALS; ANTIGENS, NEOPLASM; BONE REMODELING; CHONDROCYTES; HMGB1 PROTEIN; HUMANS; IMMUNITY, INNATE; LIGANDS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; OSTEOBLASTS; OSTEOCLASTS; S100 PROTEINS;

EID: 79955956798     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Teitelbaum, S.L., and F.P. Ross. Genetic regulation of osteoclast development and function. Nat Rev Genet 4, 638-649 (2003) (Pubitemid 36917505)
2. Boyle, W.J., W.S. Simonet, and D.L. Lacey. Osteoclast differentiation and activation. Nature 423, 337-342 (2003) (Pubitemid 40852708)
3. Teitelbaum, S.L. Bone resorption by osteoclasts. Science 289, 1504-1508 (2000)
4. Tanaka, S., N. Takahashi, N. Udagawa, T. Tamura, T. Akatsu, E.R. Stanley, T. Kurokawa, and T. Suda. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest 91, 257-263 (1993) (Pubitemid 23037280)
5. Yasuda, H., N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S. Mochizuki, A. Tomoyasu, K. Yano, M. Goto, A. Murakami, E. Tsuda, T. Morinaga, K. Higashio, N. Ud agawa, N. Takahashi, and T. Suda. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95, 3597-3602 (1998)
6. Lacey, D.L., E. Timms, H.L. Tan, M.J. Kelley, C.R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, H. Hsu, J. Sullivan, N. Hawkins, E. Davy, C. Capparelli, A. Eli, Y.X. Qian, S. Kaufman, I. Sarosi, V. Shalhoub, G. Senaldi, J. Guo, J. Delaney, and W.J. Boyle. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 (1998) (Pubitemid 28180851)
7. Boyce B.F., Z. Yao, and L. Xing. Osteoclasts have multiple roles in bone in addition to bone resorption. Crit. Rev. Eukaryot. Gene Expr. 19, 171-180 (2009)
8. Hadjidakis, D.J., and I.I. Androulakis. Bone remodeling. Ann N Y Acad Sci. 1092, 385-396 (2006) (Pubitemid 47092355)
9. Bucciarelli, L.G., T. Wendt, L. Rong, E. Lalla, M.A. Hofmann, M.T. Goova, A. Taguchi, S.F. Yan, S.D. Yan, D.M. Stern, and A.M. Schmidt. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 59, 1117-1128 (2002)
10. Bierhaus, A., P.M. Humpert, D.M. Stern, B. Arnold, and P.P. Nawroth. Advanced glycation end product receptormediated cellular dysfunction. Ann N Y Acad Sci 1043, 676-680 (2005) (Pubitemid 41123959)
11. Yamagishi S., and T. Matsui. Soluble form of a receptor for advanced glycation end products (sRAGE) as a bioma rker. Front Biosci. 2, 1184-1195 (2010)
12. Chavakis, T., A. Bierhaus, and P.P. Nawroth. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect 6, 1219-1225 (2004) (Pubitemid 39370091)
13. Zhou, Z., D. Immel, C.X. Xi, A. Bierhaus, X. Feng, L. Mei, P. Nawroth, D.M. Stern, and W.C. Xiong. Regulation of osteoclast function and bone mass by RAGE. J Exp Med 203, 1067-1080 (2006)
14. Ding, K.H., Z.Z. Wang, M.W. Hamrick, Z.B. Deng, L. Zhou, B. Kang, S.L. Yan, J.X. She, D.M. Stern, C.M. Isales, and Q.S. Mi. Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss. Biochem Biophys Res Commun 340, 1091-1097 (2006) (Pubitemid 43083390)
15. Lalla, E., I.B. Lamster, M. Feit, L. Huang, A. Spessot, W. Qu, T. Kislinger, Y. Lu, D.M. Stern, and A.M. Schmidt. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest 105, 1117-1124 (2000) (Pubitemid 30217696)
16. Pullerits R, M. Bokarewa, L. Dahlberg, and A. Tarkowski. Synovial fluy id expression of autoantibodies specific for RAGE relates to less erosive course of rheumatoid arthritis. Rheumatology. 46, 1367-1371 (2007) (Pubitemid 47244516)
17. Chavakis, T., A. Bierhaus, N. Al-Fakhri, D. Schneider, S. Witte, T. Linn, M. Nagashima, J. Morser, B. Arnold, K.T. Preissner, and P.P. Nawroth. The pattern recognition receptor (RAGE) is a counter receptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 198, 1507-1515 (2003) (Pubitemid 37467165)
18. Hudson B.I., A.Z. Kalea, M. Del Mar Arriero, E. Harja, E. Boulanger, V. D'Agati, and A.M. Schmidt. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration though activation f Rac-1 and Cdc42. J. Biol. Chem. 283, 34457-34468 (2008)
19. Cecil, D.L., K. Johnson, J. Rediske, M. Lotz, A.M. Schmidt, and R. Terkeltaub. Inflammation induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products. J. Immunol. 175, 8296-8302 (2005) (Pubitemid 41798395)
20. Yammani, R.R., C.S. Carlson, A.R. Bresnick, and R.F. Loeser. Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: role of the receptor for advanced glycation end products. Arthritis Rheum. 54, 2901-2911 (2006) (Pubitemid 44497769)
21. Stolzing, A., D. Sellers, O. Llewelyn, and A. Scutt. Diabetes induced changes in rat mesenchymal stem cells. Cells Tissues Organs 191, 453-465 (2010)
22. Philip, B.K., P.J. Childress, A.G. Robling, A. Heller, P.P. Nawroth, A. Bierhaus, and J.P. Bidwell. RAGE supports parathyroid hormone-induced gains in femoral trabecular bone. Am J Physiol Endocrinol Metab 298, E714-725 (2010)
23. Robling, A.G., P. Childress, J. Yu, J. Cotte, A. Heller, B.K. Philip, and J.P. Bidwell. Nmp4/CIZ suppresses parathyroid hormone-induced increases in trabecular bone. J Cell Physiol 219, 734-743 (2009)
24. Lotz, M.T., and K.J. Tracey. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5, 331-342 (2005) (Pubitemid 40516158)
25. Scaffidi, P., T. Misteli, and M.E. Bianchi. Release of chromatin protein HMGB1 by necrotic cells triggers inflamm ation. Nature 418, 191-195 (2002) (Pubitemid 34773774)
26. Bidwell, J.P., J. Yang, and A.G. Robling. Is HMGB1 an osteocyte alarmin? Journal of Cellular Biochemistry 103, 1671-1680 (2008) (Pubitemid 351501901)
27. Yang, J., R. Shah, A.G. Robling, E. Templeton, H. Yang, K.J. Tracey, and J.P. Bidwell. HMGB1 is a boneactive cytokine. Journal of Cellular Physiology 214, 730-739 (2008)
28. Charoonpatrapong, K., R. Shah, A.G. Robling, M. Alvarez, D.W. Clapp, S. Chen, R.P. Kopp, F.M. Pavalko, J. Yu, and J.P. Bidwell. HMGB1 expression and release by bone cells. J Cell Physiol 207, 480-490 (2006)
29. Andersson, U., and H.E. Harris. The role of HMGB1 in the pathogenesis of rheumatic disease. Biochimica et Biophysica Acta 1799, 141-148 (2010)
30. Sundberg, E., C. Grundtman, E. Af Klint, J. Lindberg, S. Ernestam, A.K. Ulfgren, H.E. Harris, and U. Andersson. Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthri tis patients - a prospective clinical study. Arthritis Research & Therapy 10, R33 (2008)
31. Ostberg, T., H. Wahamaa, K. Palmblad, N. Ito, P. Stridh, M. Shoshan, M.T. Lotze, H.E. Harris, and U. Andersson. Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis. Arthritis Research & Therapy 10, R1 (2008)
32. Zetterstrom, C.K., W. Jiang, H. Wahamaa, T. Ostberg, A.C. Aveberger, H. Schierbeck, M.T. Lotze, U. Andersson, D.S. Pisetsky, and H. Erlandsson Harris. Pivotal advance: inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate. J Leukoc Biol. 83, 31-38 (2008)
33. Palmblad, K., E. Sundberg, M. Diez, R. Soderling, A.C. Aveberger, U. Andersson, and H.E. Harris. Morphological characterization of intra-articular HMGB1 expression during the course of collagen-induced arthritis. Arthritis Research & Therapy 9, R35 (2007)
34. Zhou, Z., J.Y. Han, C.X. Xi, J.X. Xie, X. Feng, C.Y. Wang, L. Mei, and W.C. Xiong. HMGB1 regulates RANKL-induced osteoclastogenesis in a manner dependent on RAGE. J Bone Miner Res 23, 1084-1096 (2008) (Pubitemid 351915731)
35. Bonaldi, T., F. Talamo, P. Scaffidi, D. Ferrera, A. Porto, A. Bachi, A. Rubartelli, A. Agresti, and M.E. Bianchi. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. Embo J 22, 5551-5560 (2003) (Pubitemid 37279964)
36. Orlova, V.V., E.Y. Choi, C. Xie, E. Chavakis, A. Bierhaus, E. Ihanus, C.M. Ballantyne, C.G. Gahmberg, M.E. Bianchi, P.P. Nawroth, and T. Chavakis. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. Embo J 26, 1129-1139 (2007)
37. Taniguchi, N., K. Yoshida, T. Ito, M. Tsuda, Y. Mishima, T. Furumatsu, L. Ronfani, K. Abeyama, K. Kawahara, S. Komiya, I. Maruyama, M. Lotz, M.E. Bianchi, and H. Asahara. Stage-specific secretion of HMGB1 in cartilage regulates endochondral ossification. Mol Cell Biol 27, 5650-5663 (2007) (Pubitemid 47257823)
38. Taniguchi, N., B. Carames, Y. Kawakami, B.A. Amendt, S. Komiya, and M. Lotz. Chromatin protein HMGB2 regulates articular cartilage surface maintenance via beta-catenin pathway. Proc Natl Acad Sci U S A 106, 16817-16822 (2009)
39. Saito, M., and K. Marumo. Collagen cross-link s as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 21, 195- 214 (2010)
40. Thornalley, P.J. Endogenous alpha-oxo aldehydes and formation of protein and nucleotide advanced glycation endproducts in tissue damage. Novartis Found Symp 285, 229-243 (2007)
41. Thornalley, P.J. Dietary AGEs and ALEs and risk to human health by t heir interaction with the receptor for advanced glycation endproducts (RAGE) - an introduction. Mol Nutr Food Res 51, 1107-1110 (2007) (Pubitemid 47522803)
42. Hein, G.E. Glycation endproducts in osteoporosis - is there a pathophysiologic importance? Clin Chim Acta 371, 32-36 (2007) (Pubitemid 44164644)
43. Kume, S., S. Kato, S. Yamagishi, Y. Inagaki, S. Ueda, N. Arima, T. Okawa, M. Kojiro, and K. Nagata. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 20, 1647-1658 (2005) (Pubitemid 41243553)
44. Mercer, N., H. Ahmed, S.B. Etcheverry, G.R. Vasta, and A.M. Cortizo. Regulation of advanced glycation end product (AGE) receptors and apoptosis by AGEs in osteoblast-like cells. Mol Cell Biochem 306, 87-94 (2007) (Pubitemid 350001820)
45. Alikhani, M., Z. Alikhani, C. Boyd, C.M. MacLellan, M. Raptis, R. Liu, N. Pischon, P.C. Trackman, L. Gerstenfeld, and D.T. Graves. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 40, 345-353 (2007) (Pubitemid 46054556)
46. Franke, S., H. Siggelkow, G. Wolf, and G. Hein. Advanced glycation endproducts influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts. Arch Physiol Biochem 113, 154-161 (2007) (Pubitemid 47547388)
47. Sanguineti, R., D. Storace, F. Monacelli, A. Federici, and P. Odetti. Pentosidine effects on human osteoblasts in vitro. Ann N Y Acad Sci 1126, 166-172 (2008) (Pubitemid 351589306)
48. Santana, R.B., L. Xu, H.B. Chase, S. Amar, D.T. Graves, and P.C. Trackman. A role for advanced glycation end products in diminished bone healing in type 1 diabetes. Diabetes 52, 1502-1510 (2003) (Pubitemid 36666207)
49. Cortizo, A.M., M.G. Lettieri, D.A. Barrio, N. Mercer, S.B. Etcheverry, and A.D. McCarthy. Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK). Mol Cell Biochem 250, 1-10 (2003) (Pubitemid 37045717)
50. Schurman, L., A.D. McCarthy, C. Sedlinsky, M.V. Gangoiti, V. Arnol, L. Bruzzone, and A.M. Cortizo. Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp Clin Endocrinol Diabetes 116, 333-340 (2008) (Pubitemid 351947863)
51. Mercer, N., H. Ahmed, A.D. McCarthy, S.B. Etcheverry, G.R. Vasta, and A.M. Cortizo. AGER3/ galectin-3 expression in osteoblast-like cells: regulation by AGEs. Mol Cell Biochem 266, 17-24 (2004) (Pubitemid 39562303)
52. Ogawa, N., T. Yamaguchi, S. Yano, M. Yamauchi, M. Yamamoto, and T. Sugimoto. The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res 39, 871-875 (2007)
53. Miyata, T., R. Kawai, S. Taketomi, and S.M. Sprague. Possible involvement of advanced glycation end-products in bone resorption. Nephrol Dial. Transplant. 5, 54-57 (1996) (Pubitemid 27062912)
54. Miyata, T., K. Notoya, Yoshida K, Horie K, Maeda K, Kurokawa K, and Taketomi S. Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J. Am. Soc. Nephrol. 8, 260-270 (1997) (Pubitemid 127455881)
55. McCarthy, A.D., S.B. Etcheverry, L. Bruzzone, G. Lettieri, D.A. Barrio, and A.M. Cortizo. Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress. BMC Cell Biol 2, 16 (2001)
56. Marenholz, I., C.W. Heizmann, and G. Fritz. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 322, 1111-1122 (2004) (Pubitemid 39164640)
57. Donato, R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 60, 540-551 (2003)
58. Donato, R. RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr Mol Med 7, 711-724 (2007)
59. Povysil, C., R. Kana, and M. Horak. S-100 protein positivity in osteogenic tumours and tumour-like bone forming lesions. Cesk Patol 44, 59-61 (2008)
60. Balmain, N., F. Moutahir, C.W. Heizmann, and M. Lieberherr. Immunolocalization of S100A2 calciumbinding protein in cartilage and bone cells. Cell Mol Biol (Noisy-le-grand) 49, 485-486 (2003)
61. Cecil, D.L., and R. Terkeltaub. Transamidation by transglutaminase 2 transforms S100A11 calgranulin into a procatabolic cytokine for chondrocytes. J Immunol 180, 8378-8385 (2008)
62. Masui, F., S. Ushigome, and K. Fujii. Clear cell chondrosarcoma: a pathological and immunohistochemical study. Histopathology 34, 447-452 (1999) (Pubitemid 29244170)
63. Hasegawa, T., T. Hirose, R. Sakamoto, K. Seki, T. Ikata, and K. Hizawa. Mechanism of pain in osteoid osteomas: an immunohistochemical study. Histopathology 22, 487-491 (1993) (Pubitemid 23168590)
64. Chano, T., K. Matsumoto, M. Ishizawa, S. Morimoto, S. Hukuda, H. Okabe, H. Kato, and S. Fujino. Analysis of the presence of osteocalcin, S-100 protein, and proliferating cell nuclear antigen in cells of various types of osteosarcomas. Eur J Histochem 40, 189-198 (1996) (Pubitemid 27005894)
65. Schofield, J.B., T. Krausz, G.W. Stamp, C.D. Fletcher, C. Fisher, and J.G. Azzopardi. Ossifying fibromyxoid tumour of soft parts: immunohistochemical and ultrastructural analysis. Histopathology 22, 101-112 (1993) (Pubitemid 23067130)
66. Carbone, A., A. Poletti, R. Manconi, S. Sulfaro, and R. Volpe. S-100 protein immunostaining in terato matous welldifferentiated tissues. Histopathology 11, 980-983 (1987) (Pubitemid 17142460)
67. Kato, C., T. Kojima, M. Komaki, K. Mimori, W.R. Duarte, K. Takenaga, and I. Ishikawa. S100A4 inhibition by RNAi upregulates osteoblast related genes in periodontal ligament cells. Biochem Biophys Res Commun 326, 147-153 (2005) (Pubitemid 39573212)
68. Duarte, W.R., T. Shibata, K. Takenaga, E. Takahashi, K. Kubota, K. Ohya, I. Ishikawa, M. Yamauchi, and S. Kasugai. S100A4: a novel negative regulator of mineralization and osteoblast differentiation. J Bone Miner Res 18, 493-501 (2003) (Pubitemid 36241066)
69. Yoshida, T., A. Flegler, A. Kozlov, and P.H. Stern. Direct inhibitory and indirect stimulatory effects of RAGE ligand S100 on sRANKL-induced osteoclastogenesis. J Cell Biochem 107, 917-925 (2009)
70. Luo, X., K.A. Sharff, J. Chen, T.C. He, and H.H. Lu. S100A6 expression and function in human osteosarcoma. Clin Orthop Relat Res 466, 2060-2070 (2008)
71. Vassar, R., and M. Citron. Abeta-generating enzy mes: recent advances in beta- and gamma-secretase research. Neuron 27, 419-422 (2000)
72. Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81, 741-766 (2001) (Pubitemid 32267077)
73. McLeod, J., N. Curtis, H.D. Lewis, M.A. Good, M.J. Fagan, and P.G. Genever. Gamma-secretase-dependent cleavage of amyloid precursor protein regulates osteoblast behavior. Faseb J 23, 2942-2955 (2009)